APP and Alzheimer disease: We and others showed in various in vitro and mice AD models that these alterations could be ascribed to the β-secretase-derived APP C-terminal fragment (C99), rescued by β-secretase inhibitors and exacerbated by γ-secretase blockers [11, 39, 40].